Introduction
On March 6, 2025, a landmark agreement was formalized at the European Investment Bank (EIB) Group Forum in Luxembourg, marking a pivotal moment for public health in Lebanon. Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), and Thomas Östros, Vice-President of the European Investment Bank (EIB Global), signed a €10 million grant agreement aimed at fortifying Lebanon’s strained healthcare landscape.
This strategic partnership is designed to address the dual challenges of infrastructure collapse and the rising prevalence of non-communicable diseases (NCDs) within the country. By re-establishing critical diagnostic capabilities and ensuring a steady supply of life-saving medications, the initiative represents a systemic effort to stabilize a healthcare sector that has been grappling with years of economic volatility and regional instability.
The Core Pillars of the Initiative
The €10 million grant is not merely a financial injection; it is a surgical intervention into the backbone of Lebanon’s medical system. The initiative rests on two primary objectives:
1. Re-establishing the Central Public Health Laboratory (CPHL)
The Central Public Health Laboratory has historically served as the cornerstone of Lebanon’s disease surveillance and diagnostic capacity. Years of neglect, lack of funding, and the pressures of the recent humanitarian crises have rendered this facility largely inoperative. The restoration of the CPHL is essential for:
- Disease Surveillance: Monitoring outbreaks of infectious diseases in real-time.
- Quality Control: Ensuring the safety of food and water supplies across the country.
- Diagnostic Reliability: Providing the high-level testing necessary for public health emergencies, reducing the country’s reliance on fragmented private laboratory networks.
2. Medication Access for Chronic Disease Patients
The second pillar focuses on the immediate delivery of healthcare to the most vulnerable. With the currency devaluation significantly inflating the cost of imported medicines, thousands of Lebanese citizens have been forced to forgo treatment for chronic conditions. This initiative will prioritize:
- Chronic Disease Management: Providing a consistent supply chain for patients suffering from diabetes, cardiovascular diseases, and cancer.
- Direct Patient Support: Ensuring that over 50,000 individuals receive the essential pharmaceutical care required to prevent life-threatening complications.
Chronology of the Crisis and Intervention
The necessity for this intervention did not emerge in a vacuum. To understand the gravity of this agreement, one must look at the timeline of the deterioration of Lebanon’s health sector.
- Pre-2019: Lebanon boasted one of the most advanced healthcare systems in the Middle East, characterized by a mix of high-quality private hospitals and functional public health institutions.
- 2019–2021: The onset of the severe financial crisis, coupled with the COVID-19 pandemic and the devastating 2020 Beirut Port explosion, brought the system to the brink of collapse.
- 2022–2024: Hyperinflation rendered essential imported medicines unaffordable for the average citizen. Hospitals faced frequent power outages and a mass exodus of healthcare professionals.
- March 6, 2025: The EIB Global and WHO sign the €10 million agreement in Luxembourg, signaling a shift from emergency humanitarian relief to systemic health system strengthening.
Supporting Data: The Burden of Disease in Lebanon
The decision to focus specifically on chronic diseases is backed by sobering public health data. According to WHO and local health ministry assessments, non-communicable diseases are the leading cause of morbidity and mortality in Lebanon.
- Cardiovascular Disease: Responsible for an estimated 40–45% of total deaths in the country.
- Cancer Incidence: Lebanon reports one of the highest cancer incidence rates in the region, with the cost of chemotherapy and radiotherapy becoming inaccessible for a large segment of the population.
- Diabetes Prevalence: With over 15% of the adult population living with diabetes, the lack of insulin and standardized testing kits has led to an uptick in preventable emergency room visits and amputations.
By targeting these 50,000 individuals, the WHO and EIB are effectively preventing a secondary crisis of chronic-disease-related mortality that would otherwise overwhelm the remaining public hospital infrastructure.
Official Responses and Strategic Rationale
The Perspective of the World Health Organization
Dr. Tedros Adhanom Ghebreyesus emphasized that the agreement serves as a model for international cooperation in fragile settings. "Public health is not a luxury; it is the fundamental right of every individual, regardless of the economic situation of their country," Dr. Tedros stated during the signing ceremony. He noted that the WHO’s role is to ensure that the funds are translated into tangible outcomes—specifically, that the laboratory is restored to international biosafety standards and that the medication supply chain is transparent and efficient.
The Perspective of EIB Global
Thomas Östros, Vice-President of the EIB, highlighted the bank’s commitment to "Human Capital" as part of its external development mandate. "The EIB is proud to partner with the WHO to support the people of Lebanon. Our investment is aimed at building resilience. By restoring the Central Public Health Laboratory, we are not just fixing a building; we are securing the nation’s health security against future threats," Östros remarked. He added that the EIB’s involvement signals to the international community that Lebanon remains a priority for sustainable development investment.
Implications for the Future of Lebanon’s Health System
Restoring Public Trust
One of the most significant, though intangible, impacts of this initiative is the restoration of public trust in the state’s ability to provide healthcare. When the public health laboratory is functional, the government can once again take the lead in outbreak prevention and health regulation, shifting the burden away from NGOs and private entities that have been filling the gap for years.
A Model for Donor Engagement
The collaboration between a financial institution (EIB) and a technical health agency (WHO) offers a blueprint for future development aid. By leveraging the financial expertise of the EIB to fund the technical programs of the WHO, the project minimizes bureaucratic overlap and maximizes the impact of the €10 million.
Economic Stabilization through Health
Healthcare is a major economic driver. By reducing the number of people who fall out of the workforce due to chronic illness, this initiative indirectly contributes to the stabilization of the Lebanese economy. A healthy population is more productive and places less strain on the national budget in the long term.
Challenges and Monitoring
While the agreement is a major victory, stakeholders acknowledge the challenges that lie ahead. Implementing large-scale infrastructure projects in a volatile economic climate requires rigorous oversight.
- Procurement and Logistics: Ensuring that medicines reach the most vulnerable—and not the black market—will require the implementation of digital tracking systems supported by the WHO.
- Sustainability: The €10 million grant is an initial investment. The long-term challenge will be to ensure that the Lebanese Ministry of Public Health can integrate these restored services into its recurring budget to ensure they do not collapse once the initial grant is exhausted.
Conclusion
The partnership between the World Health Organization and the European Investment Bank represents a critical lifeline for Lebanon. By addressing the fundamental need for diagnostic infrastructure and essential medications, this €10 million grant is a step toward preventing a total health system collapse.
As the project moves into its implementation phase, the global community will be watching closely. The success of this initiative will depend on the synergy between international expertise and local commitment. Ultimately, the re-establishment of the Central Public Health Laboratory and the support for 50,000 chronic disease patients will serve as a testament to the fact that international cooperation can, and does, provide a path toward stability in even the most challenging circumstances.
For the people of Lebanon, this is more than just a fiscal arrangement; it is a tangible promise that their right to health is being defended at the highest levels of global governance.
For further information regarding this initiative, please contact the WHO Media Team or the European Investment Bank Press Office.
About the Author
